click below
click below
Normal Size Small Size show me how
CHF pharm
pharmacology of CHF
| Question | Answer |
|---|---|
| glycosides | inhibits Na,K-ATPase resulting in increased intracellular sodium and decreased intracellular potassium |
| glycosides | positive inotrpic effects, increases systemic vascular resistance and the constriction of smooth muscle in veins |
| glycosides | improves renal blood flow, increases vagal activity, decreased sympathetic tone |
| digoxin | oral or IV enteric bacteria may inactivate some |
| digoxin | rapid clearance, eliminated renally |
| digitoxin | excreted by bile, metabolized by liver, may set up enterhepatic circulation |
| glycosides | can be fatal, arrythmias, GI( anorexia, nausea, vomiting, diarrhea) CNS( disorientation and visual disturbances--> can be treated with potassium, phenytoin or lidocaine |
| bipyridines | inhibit phosphodiesterase, increase myocardial contractility by increasing inward calcium flux in heart during the action potential, vasodilating effects, increases in cAMP |
| bipyridines | inamrinone and milrinone |
| inamrinone | nausea and vomiting, arrythmias, thrombocytopenia, and liver enzyme changes |
| milrinone | less bone marrow and liver toxicities, still cause arrythmias |
| beta one agonist | dobuatmine |
| beta one agonist | produces increase in cardiac output with a decrease in ventricular filling pressure |
| beta one agonist | some tachycardia and and increased in myocardial oxygen consumption have been reported |